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Abstract
Loss of the DNA mismatch repair protein MSH3 leads to the development of a variety of tumors
in mice without significantly affecting survival rates, suggesting a modulating role for the MutSβ
(MSH2-MSH3) complex in late onset tumorigenesis. To better study the role of MSH3 in tumor
progression, we crossed Msh3−/− mice onto a tumor predisposing p53-deficient background.
Survival of Msh3/p53 mice was not reduced compared to single p53 mutant mice; however, the
tumor spectrum changed significantly from lymphoma to sarcoma, indicating MSH3 as a potent
modulator of p53-driven tumorigenesis. Interestingly, Msh3−/− mouse embryonic fibroblasts
displayed increased chromatid breaks and persistence of γH2AX foci following ionizing radiation,
indicating a defect in DNA double strand break repair. Msh3/p53 tumors showed increased loss of
heterozygosity, elevated genome-wide copy number variation, and a moderate microsatellite
instability phenotype compared to Msh2/p53 tumors, revealing that MSH2-MSH3 suppresses
tumorigenesis by maintaining chromosomal stability. Our results show that the MSH2-MSH3
complex is important for the suppression of late onset tumors due to its role in DNA double strand
break repair as well as in DNA mismatch repair. Furthermore, they demonstrate that MSH2-
MSH3 suppresses chromosomal instability and modulates the tumor spectrum in p53-deficient
tumorigenesis, and possibly plays a role in other chromosomally unstable tumors as well.
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Introduction
DNA mismatch repair (MMR) complexes function primarily in the detection and repair of
mismatched bases that result from erroneous replication. Two heterodimeric MutS homolog
(MSH) complexes, consisting of either MSH2-MSH6 (MutSα) or MSH2-MSH3 (MutSβ),
are responsible for the recognition of these mismatched bases. MSH2-MSH6 binds to single
base-base mismatches and small insertions/deletions (IDLs), whereas MSH2-MSH3 has a
higher affinity for ≥2 base IDLs (1, 2). Germline mutations in MSH2 and MSH6 but not
MSH3 are responsible for hereditary non-polyposis colorectal cancer/Lynch syndrome
(HNPCC/LS); however, an (A)8 tract in the coding region of MSH3 was found to be
frequently affected by frameshift mutations in MMR-deficient colorectal tumors, resulting in
loss of MSH3 protein expression (3). In addition to its role in MMR, yeast studies revealed
that during non-conservative homologous recombination, the MSH2-MSH3 complex is
required to remove nonhomologous DNA ends during both the initiation of gene conversion
and the resolution of single-strand annealing (SSA) intermediates that are initiated by a
double strand break (DSB)(4, 5). SSA is a subset of the homologous recombination pathway
for repairing spontaneous and induced DSBs that arise between repeated sequences
occurring in cis. MSH2 and MSH3 recognize and stabilize the nonhomologous 3′ tails at the
junction of double-stranded and single-stranded DNA to aid in either the recruitment or
cleavage activity of Rad1-Rad10 (6). Although the mechanistic contribution of MSH3 in
MMR and DSBR was thought to be overlapping, recent studies have shown that these two
MSH3 activities are molecularly distinct (7). MSH2-MSH3 is also involved in triplet repeat
(CAG·CTG) expansion diseases such as Huntington and myotonic dystrophy, and it has
been shown in several mouse models that MSH2 and MSH3 are absolutely required to
generate these expansions (8–12).
Previous observations showed that inactivation of Msh3 in mice leads to a moderate defect
in the repair of insertion/deletion but not base-base mismatches (13), which might explain
the absence of MSH3 mutations in HNPCC/LS families. Among other tumors, Msh3−/−
mice developed gastrointestinal tumors late in life, which corresponds with loss of MSH3
expression in late onset sporadic colorectal cancer (CRC) in humans (14). In human cancers,
loss of MSH3 is associated with an MSI-low (MSI-L) phenotype at dinucleotide repeats and
elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) (15, 16).
Loss or silencing of MSH3 also frequently occurs in a variety of other cancers, including
non-small cell lung (17), ovarian, bladder (18), and breast (19) cancer. MSH3
polymorphisms were found to be associated with sporadic colorectal (14, 20, 21), prostate
(22), and lung (23) cancer. These findings correlate with a recent report that unlike MutSα,
the MutSβ complex is abundant in the majority of mouse tissues (24). Taken together, these
studies indicate that MSH2-MSH3 might be important for tumor suppression in multiple
tissues and especially in cases of late onset tumorigenesis.
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Previous studies in mice showed that loss of Msh2 is sufficient to initiate and significantly
accelerate tumorigenesis, especially in p53-deficient mice, and that tumorigenesis is
associated with an MSI-high (MSI-H) phenotype (25). The MSH2-MSH6 complex is
essential for the repair of base/base mismatches, and loss of either MSH2 or MSH6 therefore
results in generation of a severe mutator phenotype and early onset cancers. In contrast, the
absence of MSH3 mutations in early onset HNPCC/LS tumors and the late onset tumor
phenotype in Msh3−/− mice indicate that MSH3 is likely not involved in tumor initiation. To
determine a possible role for MSH2-MSH3 in tumor progression, we crossed Msh3 null
mice onto the tumor predisposing p53 null background to create cohorts of both
Msh3−/−p53−/− and Msh3−/−p53+/− mice, compared their cancer predisposition phenotype
to MMR-deficient Msh2/p53 mutant mice and analyzed the underlying molecular
mechanisms. Although the effects of both Msh2- and Msh3-deficiency manifest from the
earliest stages of life, tumor onset in Msh3−/−p53−/− mice occurred later in life in contrast to
the early onset tumorigenesis in Msh2−/−p53−/− mice. We found that due to its role in
DSBR rather than MMR, loss of Msh3 alters the tumor spectrum in p53 mutant mice by
modulating the characteristics of the chromosomal instability (CIN) phenotype, resulting in
elevated sarcomagenesis. We conclude that germline mutations in Msh3 can cause late onset
tumorigenesis with various genomic signatures and modulate the tumor spectrum on cancer
predisposing backgrounds.
Results
Altered cancer phenotype and elevated sarcomagenesis in Msh3/p53 mutant mice
To accelerate tumorigenesis in Msh3 null mice and study tumor progression, we intercrossed
Msh3+/− and p53+/− knockout mice and generated two cohorts of mutant mice carrying
homozygous mutations in Msh3 and either homozygous (Msh3−/−p53−/−) or heterozygous
(Msh3−/−p53+/−) mutations in p53. To compare loss of Msh3 to the classic MMR
phenotype, additional Msh2−/−p53−/− and Msh2−/−p53+/− cohorts were generated by
intercrossing Msh2+/− and p53+/− mice.
Msh3−/−p53−/− double mutant mice showed reduced survival (median survival time 5
months, Figure 1a)when compared with Msh3−/− alone (22 months)(13), but not when
compared with p53−/− single mutant mice (p = .31, Figure 1a). Msh3−/−p53+/− and p53+/−
mice also showed similar survival rates (p = .11), suggesting that loss of Msh3 does not
contribute to the initiation or acceleration of tumorigenesis. In contrast, Msh2−/−p53−/− and
Msh2−/−p53+/− mice showed significantly reduced survival compared to p53−/− (2 vs. 6
months, p < .001) and p53+/− (5 vs. 16 months, p< .001) mice respectively, confirming the
strong tumorigenic MMR-deficient phenotype that has previously been described for
Msh2−/− (26–28), Msh2−/−p53−/− (25), and Msh2−/−p53+/− (29) mice.
The tumor spectrum of p53−/− mice is dominated by lymphomas, but also includes sarcomas
and carcinomas (30). Surprisingly, loss of Msh3 induced a significant shift in the distribution
of the various tumor types in p53 mutant mice: twice as many sarcomas were found in
Msh3−/−p53−/− (32% vs. 17%, p = .04) and Msh3−/−p53+/− mice (53% vs. 30%, p = .04,
Figure 1b) compared to tumors from p53−/− and p53+/− mice, respectively. In contrast,
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nearly 100% of MMR-deficient Msh2−/−p53−/− and Msh2−/−p53+/− mice succumbed to
thymic lymphoma. Only a small number of Msh3/p53 mice developed gastrointestinal
tumors. When tumors were analyzed for their MSI phenotype, which is the hallmark of
MMR-deficiency, we found that most tumors from Msh2−/−p53−/− or Msh2−/−p53+/− mice
showed MSI at the D7Mit91 and D17Mit123 dinucleotide repeats, compared to few tumors
with MSI from Msh3−/−p53 mutant mice(Figure 1c). Interestingly, none of the sarcoma
samples included in the analysis (0/12) showed MSI. The MSI-L tumor phenotype indicates
that defective MMR is not a main mechanism in Msh3−/−p53-driven tumorigenesis.
LOH but not somatic mutation leads to loss of the wild type p53 allele in Msh3−/−p53+/−
tumors
During tumorigenesis, MMR deficiency leads to the accumulation of somatic mutations in
tumor suppressor genes and oncogenes. On the other hand, tumors with CIN usually display
loss of heterozygosity (LOH) of tumor suppressor genes, which is often associated with
defective DSBR pathways(31). Since loss of the tumor suppressor p53 is a critical event in
tumorigenesis, we studied the genetic mechanisms by which the remaining p53 wild type
allele was lost in Msh3−/−p53+/− and Msh2−/−p53+/− tumors. Consistent with the MMR-
deficient phenotype, the majority of Msh2−/−p53+/− tumors (63%, 12/19, Table 1) showed
mutation of p53. All p53 exons were sequenced, and mutations were found in exons 4, 5, 7,
8, 9, and 11 of Msh2−/−p53+/− tumors. In contrast, no p53 mutations were detected in the
Msh3−/−p53+/− tumors (0/8); however, LOH at the wild type p53 allele occurred in almost
all of the tumors (86%, 6/7) (Figure 1d and Table 1), suggesting a possible role for MSH3 in
CIN. LOH of the wild type p53 allele was also found in some Msh2−/−p53+/− tumors (3/19,
16%), possibly reflecting loss of MSH2-MSH3 function in DSBR.
Msh3-deficient MEFs are defective in DSBR
In yeast, MSH2-MSH3 is involved in the processing of SSA recombination intermediates
during certain forms of homologous recombination (5), and loss of this function might result
in defective DSBR and contribute to the LOH phenotype in the tumors of Msh2−/−p53+/−
and Msh3−/−p53+/− mice. To investigate if mouse MSH3 functions as part of the MSH2-
MSH3 complex in the repair of DNA breaks, we first analyzed metaphases of untreated
primary mouse embryonic fibroblast (MEF) cell lines. Msh3−/− and Msh2−/− MEFs both
showed a significant increase in chromatid breaks (Figures 2a and 2b), further indicating a
defective DSBR response. Since the number of breaks in Msh6−/− cells was not significantly
different from that in wild type cells (p = .21), loss of DSBR appears to be specifically due
to the loss of MSH2-MSH3 complex function. Notably, all genotypes showed similar
numbers of translocations.
To further analyze the observed DSBR defect, Msh3−/− cells were subjected to a low dose
of ionizing radiation (1Gy) and efficient resolution of DSBs was subsequently evaluated by
counting γH2AX foci in the cell nuclei (Figure 2c). We did not observe a difference in the
number of γH2AX foci one hour after irradiation (Figure S1), which suggests that both wild
type and Msh3−/− MEFs had a comparable accumulation of DSBs at early time-points and
that γH2AX signaling is intact in Msh3−/− cells. However, two hours after irradiation the
majority of wild type cells (95%) showed background levels of 0–10 γH2AX foci per
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nucleus in contrast to only 45% of Msh3−/− cells (Figure S1). Even 6 hours post-irradiation
only 70% of Msh3−/− cells were able to adequately resolve DSBs (p< .001, Figure 2d), and
an increase of more than 10 γH2AX foci per nucleus could be seen in the remaining 30% of
nuclei. Taken together, these data demonstrate a moderate DSBR defect in Msh3-deficient
cells that is revealed by a delay in resolving DSBs.
Msh3 deletion is associated with chromosomal instability in p53-deficient tumors
To examine whether loss of MSH3 does lead to chromosomal instability during
tumorigenesis, we used spectral karyotyping (SKY) to determine whether lymphomas of
Msh3-deficient mice displayed any gross chromosomal abnormalities. In contrast to
Msh2−/−p53−/− tumor cells, which showed close to normal ploidy (40 chromosomes/cell,
Table 2), Msh3−/−p53−/− tumor cell karyotypes showed increased chromosomal instability
characterized by significantly increased aneuploidy (55 chromosomes/cell, p< .001),
translocations, deletions, duplications, and breaks (Figure 3). No specific recurring
chromosomal aberrations were found; indicating that loss of MSH3 induces general
chromosomal instability. However, the type of chromosomal changes between genotypes
tended to be different: Msh3−/−p53−/− and Msh2−/−p53−/− tumor cells showed about two
times more translocations compared to p53−/− cells (1.2 and 0.9 vs. 0.5 per cell, Table 2),
suggesting that the DSBR defect associated with loss of the MSH2-MSH3 complex that was
observed earlier contributes to this type of chromosomal rearrangement. In contrast, a trend
towards slightly higher numbers of deletions and duplications was observed in
Msh3−/−p53−/− and p53−/− cells compared to Msh2−/−p53−/− cells, reflecting the
aneuploidy phenotype that is associated with the p53−/− tumor background.
To study the increase in CIN in Msh3/p53 tumors in more detail, we used the lymphoma
samples that were used for SKY analysis in array comparative genomic hybridization
(aCGH) to analyze genome-wide copy number variation (CNV). Since loss of Msh3 induces
sarcomagenesis we also analyzed two groups of Msh3−/−p53+/− and p53−/− sarcomas
(Figure S2). Again, no increase in CNV was found to recur between samples at specific
genomic regions, indicating general chromosomal instability. Compared with
Msh2−/−p53−/− lymphoma samples, in which CNV was uncommon, this type of instability
was significantly increased in Msh3−/−p53−/− and p53−/− lymphomas (Figure 4). Log2 ratio
distributions of gains and losses (Figure S3) and subsequent cluster analysis (Figure S4)
revealed that both p53−/− and Msh3−/−p53−/− lymphomas showed a significant increase in
CNV (cluster 1) compared to Msh2−/−p53−/− tumors (cluster 3). Msh3−/−p53−/− and p53−/−
lymphoma samples clustered together (cluster 1) which indicates that the overall distribution
of CNVs throughout the genome in Msh3−/−p53−/− tumors was similar to that of p53−/−
tumors and that loss of MSH3 does not induce a specific pattern of CNV distribution.
Interestingly, the Msh3/p53 and p53 sarcoma samples (cluster 2) only showed a moderate
increase in CNV compared to Msh3/p53 and p53 lymphoma samples. However, the CNV
phenotype in Msh3/p53 sarcomas was significantly more severe than that found in Msh2/p53
lymphoma samples. Taken together, these results confirm that loss of MSH3, but not MSH2,
is associated with an increase in overall chromosomal instability in tumor genomes and that
the amount of CIN depends on the underlying predisposing genetic background and the
tissue-specific context.
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Discussion
The MMR proteins MSH2, MSH6, MLH1 and PMS2 all play a major and well-described
role in mismatch repair, and mutations in these genes have been found in patients with
HNPCC/LS. Up until now, no mutations have been found in the other MMR proteins
MSH3, MLH3 and EXO1 that could directly link them to the development of familial
colorectal cancer. Although intestinal tumors developed in Msh3(13) and Mlh3(32)
knockout mice late in life, these proteins appear to have a less pronounced role in MMR and
tumor suppression. However, they have been implicated in other processes aside from
MMR: apart from their roles in class switch recombination and somatic hypermutation (33–
36), MLH3 is essential for processing DSBs at crossovers during meiosis (37), and EXO1
has been identified as a key mediator of DNA end resection during DSBR (38).
Surprisingly, it has recently been found that MSH3 protein expression is higher in the
majority of murine tissues when compared to MSH6, suggesting important and specific roles
for MSH2-MSH3 in DNA repair and genomic instability (24). The similar phenotype of late
onset tumors with mild MSI that appeared in Msh3−/− and Exo1−/− mice led us to
hypothesize a role for MSH3 in tumor suppression via DSBR and maintenance of
chromosomal stability. In this study, we showed that in mice loss of Msh3 leads to
accumulation of unrepaired DSBs, and to a shift in tumor spectrum with increased CIN on a
p53-driven tumor predisposing background.
As described before (25), mice with combined Msh2 and p53 ablation show independent
segregation of the MSI phenotype compared to p53−/− alone, which suggests that loss of
Msh2 is dominant over the p53−/− phenotype. Furthermore, their synergism in
tumorigenesis suggests that they are not genetically epistatic. In contrast, Msh3−/−p53−/−
mice show features that are more similar to the p53−/− phenotype. The lack of synergism in
tumorigenesis and the shift in tumor spectrum towards sarcomagenesis suggest that MSH3
might not be involved in tumor initiation but rather in tumor progression by modulating the
p53-deficient phenotype. Interestingly, loss of p53 did not accelerate gastrointestinal
tumorigenesis of Msh3−/− mice since we only detected a small number of gastrointestinal
carcinomas in Msh3/p53 mutant mice (Figure 1b). Since loss of MSH3 is associated with a
variety of human cancer types, its effects might be evident on other predisposing
backgrounds, implicating MSH3 as a general modulator of cancer phenotypes. The
contribution of Msh3 deletion to tumorigenesis, however, depends on the genetic context
and subsequent mechanism of tumorigenesis in different tissues, since Msh3−/−Apc1638N
mice did not show a different tumor onset or phenotype compared to Apc1638N mice (39).
Due to the strong aneuploidy phenotype caused by loss of p53(40, 41) it was not
immediately clear whether loss of Msh3 contributed to the increase in CIN in
Msh3−/−p53−/− tumors. However, although there were not enough tumor samples available
for SKY analysis, we observed differences between tumors with combined Msh3/p53
deficiency and single p53 deficiency with a trend towards an increase in the average number
of translocations per cell for Msh3−/−p53−/− tumors compared to p53−/− alone, indicating
defective DSBR caused by loss of the MSH2-MSH3 complex in these tumors. This defect in
DSBR was also visible when we counted chromosomal aberrations in metaphase spreads,
showing a significant increase in chromatid breaks in Msh3−/− and Msh2−/− MEFs.
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Interestingly, here the number of translocations was not significantly different between wild
type, Msh3−/− and Msh2−/− MEFs, which might be due to technical difficulties with scoring
translocations in regular metaphase spreads. Alternatively, this data suggests that loss of
MSH2-MSH3-dependent DSBR results in an increase in the number of translocations during
the clonal outgrowth of p53-deficient tumors and contributes to p53-driven tumorigenesis.
The amount of chromosomal instability represented by CNV, however, is significantly
increased in Msh3−/−p53+/− tumors (Figure 4 and Figure S2) compared to the CNV
phenotype in p53+/− tumors from our previous study (48) which indicates that loss of Msh3
is contributing to the chromosomal instability phenotype in Msh3−/−p53+/− tumors.
Our observations indicate a dual function for the MutSβ complex in genome maintenance
and tumor suppression (Figure 5). Msh2-deficient mice display a strong MMR defect with
accumulation of mutations and low chromosomal instability, indicating the essential role for
MSH2 in MMR. On the other hand, a moderate DSBR defect is associated with the loss of
either MSH2 or MSH3, and whereas the mild phenotypes with regard to CIN and
tumorigenesis that are associated with the loss of MSH2-MSH3 dependent DSBR are
difficult to observe in the dominant MMR tumor phenotype of Msh2-deficient mice, we
were able to study them by deleting Msh3 on the appropriate tumor predisposing
background. Because the DSBR defect is not as severe as the defect caused by loss of other
canonical DSBR proteins, this further suggests a role for MSH3 in the repair of a subset of
DSBs, possibly substrates of the SSA pathway (6, 7). Interestingly, loss of MSH3 was
shown to be associated with accelerated tumor progression in MLH1-deficient colorectal
cancers, and it was suggested that the effect of MSH3 loss on tumor progression might be
related to another function of MSH3 unrelated to MMR, implicating its role in DNA DSBR
by SSA (3). It remains unclear whether the role of MSH3 in DSBR is dependent on its
recruitment via the MMR pathway, either during the process of homeologous recombination
or when small IDLs or DNA mismatches (42) on opposite strands are in close proximity so
as to mediate the formation of DSBs during the MMR process, or whether MSH2-MSH3
could instead be recruited directly to sites of DSBs. Regardless, MSH3 was shown to co-
localize with γH2AX and DSB foci following genotoxic stress (43, 44), which suggests that
it might be directly involved in a subset of DSBR events.
Despite the moderate defect in DSBR Msh3 deficient mice showed a significant increase in
sarcomagenesis, suggesting that loss of MSH3 targets sarcoma tumor suppressor genes and
modulates p53-dependent tumorigenesis. When we analyzed lymphomas and sarcomas for
genomic instability, Msh3−/−p53−/− and p53−/− lymphomas showed the largest increase in
CNV while Msh2−/−p53−/− mice displayed a low CNV phenotype. Interestingly, both
Msh3/p53 and p53 sarcomas displayed significantly more CNV than Msh2/p53 lymphomas,
but less CNV than Msh3/p53 and p53 lymphomas, and clustered together based on their
moderate CNV profile. This indicates that loss of Msh3 causes a repair defect that
contributes to genomic instability in a tissue-specific manner and promotes p53-driven
sarcomagenesis. Since the sarcomas in our mouse cohorts are microsatellite stable, the
increase in sarcoma incidence in Msh3/p53 mutant mice is likely caused by loss of Msh3-
dependent DSBR which contributes to the moderate CIN that is associated with
sarcomagenesis. However, loss of Msh3-dependent MMR might also play a role in p53-
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dependent sarcomagenesis by resulting in a low-level mutator phenotype that might be
difficult to detect (2, 42).
In conclusion, our data indicate for the first time that the MSH2-MSH3 protein complex is
involved in tumorigenesis through maintenance of chromosomal stability. In contrast to the
MutSα complex (MSH2-MSH6), which has a dominant role in genome maintenance by
MMR, MSH2-MSH3 functions both in MMR, indicated by an MSI-L phenotype, and
DSBR, as has been recently shown in yeast (7). Loss of MSH3 can therefore contribute to
tumorigenesis in two ways: by a mild MMR defect leading to MSI-L and low-level mutation
accumulation, and by a DSBR defect that leads to a moderate increase in CIN. Since most
sporadic colorectal cancers (CRCs) are CIN (85%) (45), the MSH2-MSH3 complex might
play an important role in suppression of late-onset sporadic cancers that are MSI-L. Future
studies should therefore include the analysis of Msh3 loss on multiple tumorigenic
backgrounds to assess a more specific role for MSH3 in tumorigenesis.
Materials and methods
Animals, tumors and survival
Msh2−/−, Msh3−/− and Msh6−/− knockout mice were previously generated in our lab (13,
28, 46). p53−/− knockout mice (47) were purchased from Jackson Laboratories. All mice
were on a congenic C57BL/6 background. Mice were intercrossed as described and
observed until they became morbid or moribund. Tumors were removed and fixed in 10%
buffered formalin or frozen at −150°C. After paraffin embedding of fixed tissue, sections
were stained with hematoxylin and eosin. Statistical analysis of tumor incidence was
completed with IBM SPSS Statistics version 20.0 (IBM Corp., Armonk, NY). The Kaplan-
Meier method was used to compare curves for survival, with significance evaluated by two-
sided log rank statistics. A Chi squared test was used to assess the influence of genotype on
the tumor spectrum.
Microsatellite instability, LOH, and mutational analysis of p53
For MSI analysis, the D7Mit91 and D17Mit123 microsatellite loci were amplified from
normal and tumor DNA and analyzed as previously described (39). Tumor DNA was also
serially diluted and analyzed for loss of the wild type p53 allele as previously described
(48). To analyze tumors for p53 mutations, primers amplifying all exons of p53 (including
both transcript variants of exon 11) were used as described (49), followed by DNA
sequencing.
Chromatid break and double strand break analysis
Primary mouse embryonic fibroblasts (MEFs, p4–6) were treated overnight with 0.1 μg/ml
colcemid (Invitrogen, Carlsbad, CA) and subsequently swelled, fixed, and dropped onto
glass slides to prepare metaphase spreads. DNA was stained using mounting medium with
DAPI (Vector Laboratories, Inc., Burlingame, CA), and at least 100 metaphases in 2–3
different cell lines were analyzed per genotype.
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For DSB analysis, MEFs were cultured on poly-L-lysine coated slides (Sigma, St. Louis,
MO), irradiated with 1 Gy, and incubated at 37°C for 30 min – 6h. Cells were fixed with
cold 1:1 methanol:acetone for 5 min, and washed twice with cold PBS for 5 min. After
blocking with 10% FBS in PBS, cells were incubated overnight with a mouse monoclonal
γH2AX antibody (Upstate, Billerica, MA; 1:500). Cells were again washed twice in cold
PBS for 5 min, and incubated for 1h at room temperature with an Alexa Fluor 488-labeled
goat anti-mouse antibody (Invitrogen). DNA was stained using mounting medium with
DAPI. The experiment was repeated three times for two different cell lines per genotype,
and a minimum of 100 cells was analyzed each time.
Metaphases and foci were counted using an Olympus BX61 microscope (Olympus America
Inc., Center Valley, PA) with Sensicam QE cooled CCD camera (PCO, Kelheim, Germany).
Significant differences between cell lines in the number of breaks or γH2AX foci were
calculated using an independent two sample t test of equal variance.
Spectral karyotyping (SKY)
Thymic lymphomas were dissociated, filtered, and resuspended as described (50). To
prepare metaphase spreads, cells were treated with colcemid for 3–6 hours, swelled, fixed,
and dropped onto clean glass slides inside a humidity chamber. SKY was performed as
previously described (51). Slides were hybridized with the combinatorially labeled whole
chromosome painting probes (Applied Spectral Imaging, Inc., Carlsbad, CA) and metaphase
images were captured using the Applied Spectral Imaging interferometer on an
epifluorescence microscope (Zeiss). SKY karyotypes were then analyzed with SkyView™
version 1.62 (Applied Spectral Imaging, Inc.). Metaphases were captured and analyzed
using the nomenclature approved by the International Committee on Standardized Genetic
Nomenclature for Mice (http://www.informatics.jax.org).
Array comparative genomic hybridization (aCGH)
Genomic DNA was isolated from frozen tumor tissue and matched normal tail tissue using
the Qiagen DNeasy kit, and hybridized to NimbleGen Mouse CGH 3×720K Whole-Genome
Tiling Arrays (Roche NimbleGen, Inc., Madison, WI) in four different experiments. To
represent the wide variation of mouse sarcoma samples but also to homogenize between
genotypes, groups were composed of one fibrohistiocytic, one hemangio- and one spindle
cell sarcoma each.
Plotting summaries of copy number changes among all samples for each genotype was done
as described before (48). In order to compare copy number changes between different sets of
samples, distributions of the (log2) ratios for the segmented data were plotted for each
sample. The tails of this distribution (weight) were used to indicate the amount of
chromosomal instability: That is, for each distribution, the proportion of data points >3 s.d.
of the distribution with the lowest variance was computed on the left and right tails, i.e.
relative copy number increase (gain) or decrease (loss) according to the aCGH data.
Samples were subsequently clustered using the k-means clustering algorithm. Consistency
of the clusters obtained was evaluated by the silhouette method(52).
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Loss of Msh3 modifies tumor phenotype of p53 null mice. (a) Tumor-free survival was
significantly different for Msh2−/−p53−/− and p53−/− mice (p< .001) and for
Msh2−/−p53+/− and p53+/− mice (p< .001). In contrast, survival was similar
forMsh3−/−p53−/− and p53−/− mice (p = .31) and for Msh3−/−p53+/− and p53+/− mice (p = .
11). Dashed lines, Msh2/p53 genotypes; solid lines, Msh3/p53 genotypes; dotted lines,
single p53 genotypes. (b) Tumor type and incidence in mice with different Msh2, Msh3, and
p53 genotypes. The percentage of sarcomas is increased in Msh3−/−p53−/− and
Msh3−/−p53+/− mice compared to p53−/− and p53+/− mice, respectively (p = .04). Also, the
carcinoma phenotype includes a small number of small intestinal tumors (Msh3−/−p53−/−,
1; Msh3−/−p53+/−, 2). (c) Microsatellite instability (MSI) analysis of tumors at the
dinucleotide loci D7Mit91 and D17Mit123, determined by the number of unstable alleles
divided by the total number of alleles scored. (d) Loss of heterozygosity (LOH) of the wild
type p53 allele (*) was demonstrated in Msh2−/−p53+/− or Msh3−/−p53+/− tumor samples
using PCR (see also Table 1). Upper band, wild type allele (540 bp); lower band, p53 null
allele (480 bp).
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Figure 2.
Loss of Msh3 induces a double strand break repair defect. (a) Metaphase spreads from
Msh2−/− (left) and Msh3−/− (right) mouse embryonic fibroblasts (MEFs). Examples of
chromatid breaks are magnified in insets. (b) Chromosomal aberrations were analyzed for
>100 metaphase nuclei per genotype in MEF cell lines. Average numbers of chromatid
breaks and translocations are shown. (c) Three categories of γH2AX foci accumulation were
defined after staining with DAPI (blue) and anti-γH2AX antibody (red): 0–5, 6–10, and >10
foci per nucleus. (d) Deficient double strand break repair was defined by accumulation of
γH2AX foci in Msh3−/− and wild type MEFs 6h after irradiation with 1Gy.
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Figure 3.
MSH3 is involved in maintaining chromosomal stability. Examples of spectral karyotypes
from lymphoma cells are shown for each genotype, indicating a close to normal karyotype
and t(1,8) for Msh2−/−p53−/−, increased aneuploidy, del1, and t(1,7) for Msh3−/−p53−/−,
and increased aneuploidy, 2del1 and del6 for p53−/−. Red boxes indicate translocations and
deletions.
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Figure 4.
Loss of Msh3 is associated with a high level of CNV. Chromosome copy number changes
were analyzed as described before (48). To account for tumor heterogeneity, large segments
with low-level copy number changes were considered as important as small segments with
high-level changes, and no arbitrary log2 ratio was used. %, percentage of samples that
showed gain (red) or loss (green). L, lymphoma; S, sarcoma.
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Figure 5.
Model representing the different functions of the Mutsβ (MSH2-MSH3) complex. Deletion
of Msh2 induces a strong MMR defect and a moderate DSBR defect, leading to a dominant
tumor phenotype with early onset tumors that are MSI-high and chromosomally stable.
Deletion of Msh3 revealed a moderate DSBR defect next to the previously described
moderate MMR defect, resulting in a modulated tumor phenotype of late onset tumors that
were MSI-low and showed increased chromosomal instability.
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Table 2
Chromosomal aberrations from SKY analysis
Tumor sample # Cells
Average # aberrations per cell (± CI 95%)
Chromosomes Translocations Deletions/Duplications
Msh3−/− p53−/− 23 55a (51–83) 1.2 (0.4–1.9) 1.0 (0.4–1.5)
Msh2−/− p53−/&minus; 26 40 (39–41) 0.9 (0.5–1.3) 0.7 (0.2–1.2)
p53−/− 17 51 (51–54) 0.5 (0.1–0.8) 1.2 (0.4–1.9)
aboth Msh3−/−p53−/− (p< .001) and p53−/− (p = .001) tumors have significantly more chromosomes per cell compared with Msh2−/−p53−/−
tumor cells
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